

## **Gastrointestinal Workgroup Recommendations to the Pharmacy and Therapeutics Committee**

Following review of the Gastrointestinal drug classes on the Preferred Drug List, the workgroup recommends the Committee consider the following:

### **Nausea Agents-Oral**

Create a new class for Emend®, termed “Substance P Receptor Antagonist”, and remove prior authorization from Emend®

Maintain Kytril® and Zofran® products as available without prior authorization

### **Proton Pump Inhibitors**

No change to the clinical edit for high dose therapy over three months

Allow Prevacid soltabs® to be available without prior authorization for persons under age 12

No other changes to current classification

### **5HT 4 Agonists**

No changes to current status